Ptc Therapeutics (PTCT) Cash & Equivalents (2012 - 2026)
Ptc Therapeutics (PTCT) posted quarterly Cash & Equivalents of $1.0 billion for Q2 2026, up 3.19% year-over-year from $1.0 billion in Q2 2025, and up 25.89% quarter-over-quarter from $834.0 million in Q1 2026.
Ptc Therapeutics (PTCT) Cash & Equivalents (2012 - 2026) Analysis & Trends
Ptc Therapeutics' Cash & Equivalents history runs 15 years deep, the most recent figure standing at $1.0 billion for Q2 2026.
- In Q2 2026, Cash & Equivalents rose 3.19% year-over-year to $1.0 billion; the TTM figure through Jun 2026 stood at $1.0 billion (up 3.19% YoY), while the FY2025 annual figure was $984.6 million, up 26.28% from the prior year.
- Cash & Equivalents for Q2 2026 stood at $1.0 billion, up from $834.0 million in the prior quarter.
- The five-year high for Cash & Equivalents was $1.5 billion in Q1 2025, with the low at $104.4 million in Q3 2022.
- The 5-year median for Cash & Equivalents is $571.2 million (2023), against an average of $576.1 million.
- The sharpest annual moves came in 2022 and 2024: Cash & Equivalents plunged 44.99% in 2022, then soared 227.39% in 2024.
- Ptc Therapeutics' Cash & Equivalents stood at $279.8 million in 2022, then surged by 112.27% to $594.0 million in 2023, then soared by 31.26% to $779.7 million in 2024, then increased by 26.28% to $984.6 million in 2025, then gained by 6.63% to $1.0 billion in 2026.
- Business Quant data shows PTCT's Cash & Equivalents at $1.0 billion in Q2 2026, $834.0 million in Q1 2026, and $984.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Ptc Therapeutics | 5.97 Bn | 3.75 Bn | 340.60 Mn | 1.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.05 Bn |
| Mar 31, 2026 | 833.99 Mn |
| Dec 31, 2025 | 984.65 Mn |
| Sep 30, 2025 | 672.62 Mn |
| Jun 30, 2025 | 1.02 Bn |
| Mar 31, 2025 | 1.48 Bn |
| Dec 31, 2024 | 779.71 Mn |
| Sep 30, 2024 | 526.00 Mn |
| Jun 30, 2024 | 654.78 Mn |
| Mar 31, 2024 | 548.36 Mn |
| Dec 31, 2023 | 594.00 Mn |
| Sep 30, 2023 | 165.16 Mn |
| Jun 30, 2023 | 208.39 Mn |
| Mar 31, 2023 | 167.50 Mn |
| Dec 31, 2022 | 279.83 Mn |
| Sep 30, 2022 | 104.42 Mn |
| Jun 30, 2022 | 158.16 Mn |
| Mar 31, 2022 | 144.18 Mn |
| Dec 31, 2021 | 189.72 Mn |
| Sep 30, 2021 | 189.82 Mn |